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Abstract The effect of cannabinoids on caffeine con-
tractures was investigated in slow and fast skeletal muscle
ﬁbers using isometric tension recording. In slow muscle
ﬁbers, WIN 55,212-2 (10 and 5 lM) caused a decrease in
tension. These doses reduced maximum tension to
67.43 ± 8.07% (P = 0.02, n = 5) and 79.4 ± 14.11%
(P = 0.007, n = 5) compared to control, respectively.
Tension-time integral was reduced to 58.37 ± 7.17% and
75.10 ± 3.60% (P = 0.002, n = 5), respectively. Using
the CB1 cannabinoid receptor agonist ACPA (1 lM)
reduced the maximum tension of caffeine contractures by
68.70 ± 11.63% (P = 0.01, n = 5); tension-time integral
was reduced by 66.82 ± 6.89% (P = 0.02, n = 5) com-
pared to controls. When the CB1 receptor antagonist
AM281 was coapplied with ACPA, it reversed the effect of
ACPA on caffeine-evoked tension. In slow and fast muscle
ﬁbers incubated with the pertussis toxin, ACPA had no
effect on tension evoked by caffeine. In fast muscle ﬁbers,
ACPA (1 lM) also decreased tension; the maximum ten-
sion was reduced by 56.48 ± 3.4% (P = 0.001, n = 4),
and tension-time integral was reduced by 57.81 ± 2.6%
(P = 0.006, n = 4). This ACPA effect was not statistically
signiﬁcant with respect to the reduction in tension in slow
muscle ﬁbers. Moreover, we detected the presence of
mRNA for the cannabinoid CB1 receptor on fast and slow
skeletal muscle ﬁbers, which was signiﬁcantly higher in
fast compared to slow muscle ﬁber expression. In conclu-
sion, our results suggest that in the slow and fast muscle
ﬁbers of the frog cannabinoids diminish caffeine-evoked
tension through a receptor-mediated mechanism.
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Introduction
Cannabinoids exert diverse biological effects on tissues by
acting at cannabinoid receptors, which belong to the
superfamily of Gi/Go protein-coupled receptors (Matsuda
et al. 1990), which are sensitive to pertussis toxin (Reisine
and Law 1992; Soderstrom et al. 2000). To date, two
cannabinoid receptors have been identiﬁed (CB1 and CB2);
the CB1 receptor is mainly located within the central ner-
vous system but also in peripheral tissues; the CB2 receptor
is found predominantly in the immune system (Chaperon
and Thiebot 1999; Matsuda et al. 1990) and is also
expressed by some neurons (Beltramo et al. 2006; Gong
et al. 2006). In the brain, CB1 receptors are highly localized
in the hippocampus, cerebellum and substantia nigra (Glass
et al. 1997). They are also located presynaptically on
peripheral nerves in gut, vas deferens, bladder (Pertwee
et al. 1996), immune (Munro et al. 1993; Parolaro 1999)
and smooth muscle cells (Filipeanu et al. 1997). However,
cannabinoid receptors also occur postsynaptically, e.g., in
the hippocampus and in skeletal muscle (Cavuoto et al.
2007a; Ortiz-Mesina et al. 2007). Cannabinoids also bind
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are expressed in skeletal muscle (Xin et al. 2005; Cavuoto
et al. 2007b).
The endogenous cannabinoid system, represented by
cannabinoid receptors, appeared early in evolution and has
been conserved (Salzet et al. 2000; McPatland et al. 2006).
In amphibians, to date only the CB1 ortholog receptor has
been found (McPatland et al. 2006; Salzet et al. 2000).
Soderstrom et al. (2000) reported the expression of CB1 in
different tissues of newt including skeletal muscle. Salio
et al. (2002) studied the distribution of CB1 receptors in
amphibian spinal cord. In 2006, Meccariello et al. reported
the expression of CB1 in several tissues of Rana esculenta.
Hollis et al. (2006) also reported the existence of CB1
receptor in the newt brain. In R. pipiens, Sa ´nchez-Pastor
et al. (2007) showed pharmacological evidence indicating
the functional presence of CB1 receptors in the neuro-
muscular junction.
Cannabinoids reduce locomotor activity. These effects
could be due to actions on the central nervous system
(Dewey 1986; San ˜udo-Pena et al. 2000). Some effects of
cannabinoids have suggested their potential therapeutic use
(as muscle relaxants or reducers of motor activity) (Baker
et al. 2000, 2001; Mackie 2006). However, more basic
research is required before their real value can be assessed.
To this end, we designed the present study to evaluate the
direct action of cannabinoids on contraction of skeletal
muscles, hoping to ﬁnd a physiological basis for some of
their effects on spasticity, spontaneous muscle activity and
reduction of motor activity (Baker et al. 2000, 2001;
DiMarzo et al. 2000; Mackie 2006; San ˜udo-Pena et al.
2000). Our primary aim was to examine the effects of the
CB1 cannabinoid agonists WIN 55,212-2 and arachido-
nylcyclopropylamide (ACPA) on caffeine contractures in
slow and fast skeletal muscle ﬁbers of R. pipiens. In
addition, in this study we found mRNA for the CB1
receptor in frog skeletal muscle. The presence of mRNA
was determined semiquantitatively and quantitatively by
PCR. Some of these results have been previously published




The study was performed on extensor digitorum longus
digiti IV and cruralis muscles or bundles (0.5 mm diame-
ter) from R. pipiens by doing molecular biology experi-
ments or by means of isometric tension recordings. Frogs
were used in accordance with the Institute for Laboratory
Animal Research’s Guide for the Care and Use of
Laboratory Animals (1996) and Alworth and Harvey
(2007). They were kept at room temperature (22–24C) and
fed with a mixture of chicken liver and cod liver oil. To
minimize pain and distress, under cold anesthesia frogs
were killed and demedullated to extract the muscles.
Tension Recording
A continuous-perfusion recording chamber with an
adjustable width and a central channel 3 cm long was used
to record tension in the bundles. The proximal end of each
bundle was ﬁxed to the wall of the chamber, while the
distal end was hooked up to the lever of a linear me-
chanoelectrical transducer (400A; Cambridge Technology,
Cambridge, MA). The bundle was stretched to 1.3 times its
resting length before any isometric-tension recording was
performed. Caffeine contractures were 240 s of duration
for slow muscle ﬁbers and 80 s for the fast muscle ﬁbers.
Solutions entered via a three-way tap situated at one end of
the central channel. Mechanical responses were evoked by
caffeine solution (see ‘‘Solutions’’), both in the control
trials and after addition of an agonist or antagonist for the
cannabinoid receptors (WIN 55,212-2, ACPA or AM281;
Tocris Bioscience, Ellisville, MO). A data-acquisition
system (CyberAmp 320; Axon Instruments, Foster City,
CA) and a Digidata 1200 (Axon Instruments) were used to
process and to store the data in a computer (Pentium 4) for
subsequent analysis. AxoScope software (pClamp 9.0,
Axon Instruments) was used for data acquisition and the
program Clampﬁt, for data analysis.
Extracting the tRNA to Detect CB1 in Extensor
Digitorum Longus and Cruralis Muscles
To extract tRNA, the procedures described by Chom-
czynski and Sacchi (1987) were used. In brief, 10 mg of
extensor digitorum longus IV or cruralis muscle in PBS
solution (Invitrogen 10010-023; GIBCO, Rockville, MD)
were extracted and transferred to a 1.5-ml tube containing
0.5 ml Trizol (15596-018; Invitrogen, Carlsbad, CA). The
tissue was homogenized, and total RNA was then extracted
using phenol-chloroform and isopropanol. To determine
the quality of RNA, electrophoresis was carried out on 1–2
lg of the total RNA using 1% agarose gel. To identify the
expression of CB1 in skeletal muscle ﬁbers of the frog, we
made a comparison of the published sequences in Gene-
Bank Delta mRNA for several species, and primers were
designed considering the conserved sequences having as
base template the Xenopus laevis sequence. Thus, the
sequence used was 50-GCAGTGTAATTTTTGTCTA-
CAG-30 (sense) and 50-GAGGGCCCCAACAAATGATT-
30 (antisense). As a positive control for CB1 receptor
expression, CaCl2 precipitation was used to transfect 70%
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coding sequence for human CB1 cannabinoid receptor. The
cDNA for CB1, inserted into the mammalian expression
vector pCI (Promega, Madisson, WI), was expressed under
the control of a cytomegalovirus (CMV) promoter.
HEK293 cell culture was grown at 37C in Dulbecco’s
modiﬁed eagle medium (GIBCO) containing 10% horse
serum and 1% antibiotic-antimycotic, under a 5% CO2
atmosphere. To carry out reverse-transcriptase polymerase
chain reaction (RT-PCR), a SuperScript
TM one-step RT-
PCR with a Platinum
 Taq kit (Invitrogen) was used and 4
lg of the total RNA from the extensor digitorum longus or
cruralis muscles was added. A DNA thermal cycler (iCy-
cler; Bio-Rad Laboratories, Hercules, CA) was used, and
the protocol consisted of the following cycles: (1) to syn-
thesize and denaturalize cDNA, we started with a 50C
cycle for 30 min, followed by a 2-min cycle at 90C; (2)
then, we ampliﬁed the cDNA using 40 cycles (each of 15 s
at 94C, 30 s at 50C and 1 min at 72C); and (3) we
ﬁnished with a ﬁnal 8-min cycle at 72C. The total reaction
mix used for this RT-PCR (50 ll) contained 4 lg of total
muscle RNA, 1 nM of each of the primers, 25 ll
2 9 reaction mix, 1 ll RT/Platinum Taq Mix and 1 llo f
5m M MgSO4. The anticipated size for CB1 receptor
mRNA was 579 bp compared with 1,053 bp for b-actin
mRNA. Electrophoresis of the RT-PCR products to sepa-
rate the components was done on a 1% agarose gel. Signals
were analyzed using Quantity one, version 9.2.1 (Bio-Rad
Laboratories).
Real-Time RT-PCR
Real-time RT-PCR was performed according to Super-
Script
TM one-step methods using a real-time RT-PCR
thermal cycler (Rotor-Gene 3000; Corbett Life Science,
Sydney, Australia). Thus, the cocktail was prepared exactly
as for conventional RT-PCR but adding the ﬂuorophore
SYBR green (SuperArray, Frederick, MD). The ﬂuores-
cence of the SYBR green indicated the expression level for
CB1 mRNA, and this was compared with an mRNA sample
of known concentration used as control. Analysis was done
using Rotor-Gene 5 software (Corbett Life Science).
Solutions
The normal saline solution contained (in mM) NaCl 117.5,
KCl 2.5 and CaCl2 1.8. The pH was adjusted to 7.4 with
imidazole Cl. Contractures were induced following rapid
substitution (1–2 s) of the normal solution by caffeine
solution (normal saline solution plus caffeine 6 mM). In
mechanical experiments, the bundle was curarized with 50
lM d-tubocurarine (Sigma, St. Louis, MO). Stock solutions
of WIN 55,212-2, ACPA and AM281—1-(2,4-
dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholi-
nyl-1H-pyrazole-3-carboxamide (Tocris Cookson, Ballwin,
MO)—at 10 mM concentration were made up in dimethyl
sulfoxide (DMSO) or ethanol (Sigma). The ﬁnal concen-
tration of DMSO in the bathing solution was \0.01%,
which has no signiﬁcant effect on caffeine or K
? con-
tractures (Velasco et al. 2003). The cruralis bundles were
incubated in the appropriate solution for 5 min before
contractures were induced using caffeine. When ACPA
was used, the experiments were performed in the dark.
Pertussis toxin (PTX; Sigma-Aldrich, St. Louis, MO) was
applied by incubating the muscle with 2 lg/ml PTX in
normal saline solution at 4C for 22–24 h before doing
experiments (Sugiura and Ko 1997). Experiments were
performed at room temperature (22–24C). PTX was
reconstituted as a stock solution (50 lg/ml) with 5 mg/ml
of bovine serum albumin (BSA, Sigma) solution in water.
Control experiments were done by incubating muscles in a
solution of BSA.
Data Analysis
Tension analysis was performed using the Clampﬁt sub-
routine (pClamp 9.0 software, Axon Instruments). Graphics
were generated by Sigmaplot 8.0 software (Systat Soft-
ware, San Jose, CA). The analyzed parameters of the
contracture were maximum tension (peak tension) and
tension-time integral (total tension). The experimental
results are presented as means ± standard error. Mean data
were subjected to Student’s t-test; differences were con-
sidered signiﬁcant at P\0.05.
Results
Presence of mRNA for Cannabinoid Receptor CB1
in Skeletal Muscle Fibers
CB1 receptors are broadly localized in the central nervous
system and in some peripheral tissues, but the presence of
these kinds of receptors in skeletal muscle has not been
determined. The presence of CB1 receptor mRNA was
determined in frog fast and slow skeletal muscle ﬁbers.
Fast muscle ﬁbers were obtained from the extensor digi-
torum longus muscle and slow muscle ﬁbers, from tonic
bundles of cruralis muscle. In Fig. 1, lane 2 shows
untransfected HEK293 cells (negative control). Lane 3
shows HEK293 cells transfected with CB1 (positive con-
trol). The expected size for CB1 was 579 bp. Lanes 4 and 5
show the expression of CB1 receptors in fast and slow
skeletal muscle ﬁbers, respectively. As can be seen, CB1
expression is very abundant in fast skeletal muscle ﬁbers
(lane 4) as its expression is comparable with induced
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although to a lesser extent, slow muscle ﬁbers also express
mRNA for CB1, shown as a faint but visible band in lane 5.
Expression of b-actin was used as a control for RNA
quality. The relationship to the mRNA expression for CB1/
b-actin was 0.99 ± 0.03 for fast muscle ﬁbers and
0.51 ± 0.10 for slow muscle ﬁbers. The difference was
statistically signiﬁcant (P = 0.002, n = 6). Thus, CB1
receptors are present in both fast and slow skeletal muscle
ﬁbers of the frog.
Real-Time RT-PCR
To further conﬁrm the existence of mRNA for CB1 in frog
skeletal muscle ﬁbers, we did quantitative analysis of CB1
mRNA levels using real-time RT-PCR. The mRNA
expression levels of CB1 receptors were checked by the
intensity of ﬂuorescence produced by SYBR green. As
with conventional RT-PCR, the expression levels were
lower in slow muscle ﬁbers than in fast muscle ﬁbers
(Fig. 2). The concentration levels for CB1 mRNA corrob-
orate the approximate 2:1 relationship between fast and
slow muscle ﬁbers, which was 5.07 lg/ll for the fast
muscle ﬁbers and 2.60 lg/ll for the slow muscle ﬁbers. To
determine the CB1 mRNA concentrations, we used a
sample with known mRNA concentration as a control.
Effects of WIN 55,212-2 on Caffeine Contractures
in Slow Muscle Fibers
It is known that cannabinoids can affect muscle activity
(Baker et al. 2000, 2001; DiMarzo et al. 2000; Mackie
2006; San ˜udo-Pena et al. 2000), but little information
exists about the mechanism of action of cannabinoids on
skeletal muscle. To determine whether cannabinoids
directly modulate tension in slow skeletal muscle ﬁbers, we
used the cannabinoid agonist WIN 55,212-2. WIN was
added to the external medium 5 min previous, to induce the
caffeine contracture, and kept throughout the contracture.
Addition of this agonist (10 lM) to the external medium
decreased the tension evoked by 6 mM of caffeine; the
maximum tension was clearly reduced to 67.43 ± 8.07%
(P = 0.02, n = 5), while tension-time integral was
reduced to 58.37 ± 7.17% (P = 0.0001, n = 5), compared
to the control (Fig. 3a). Figure 3b shows caffeine con-
tractures in normal solution before and after adding WIN 5
lM; the maximum tension was reduced to 79.4 ± 14.11%
(P = 0.007, n = 5), while tension-time integral was
reduced to 75.1 ± 3.6% (P = 0.002, n = 5). Thus, WIN at
different concentrations reduces the tension of caffeine
contractures in slow skeletal muscle ﬁbers.
Effects of ACPA on Caffeine Contractures in Slow
Muscle Fibers
To further corroborate that cannabinoids can modulate
tension in skeletal muscle ﬁbers, we examined the effects
of a selective agonist of CB1 receptors, ACPA, which is
analogous to the endocannabinoid anandamide (Hillard
Fig. 1 A 1% agarose gel showing electrophoresis results for RT-PCR
analysis of CB1 receptor. Lane 1, HindIII; lane 2, nontransfected
HEK293 cells; lane 3, transfected HEK293 cells; lane 4, frog fast
extensor digitorum longus muscle; lane 5, frog slow cruralis muscle;
lane 6, HindIII. All lanes contained actin and the CB1 primers
Fig. 2 RT-PCR expression levels for CB1 mRNA in fast and slow
frog muscles. As can be seen, ﬂuorescence began earlier in the fast
muscle (around cycle 25 vs. cycle 27 for the slow muscle). The values
for CB1 mRNA concentrations were 5.07 lg/ll for fast muscle ﬁbers
and 2.60 lg/ll for slow muscle ﬁbers. To determine the concentra-
tions of CB1 mRNA, a known mRNA concentration was used as a
control
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muscle ﬁbers. In these experiments, 1 lM of ACPA was
applied during contractures induced with caffeine (6 mM).
Figure 4 shows the results that we obtained. Figure 4a
shows caffeine contractures in a normal solution (control)
and when ACPA was applied to the bathing solution, which
decreased the muscle tension. Maximum tension was
clearly reduced compared to the control—by
68.70 ± 11.63% (P = 0.01, n = 5)—while tension-time
integral was reduced by 66.12 ± 6.89% (P = 0.02,
n = 5). In addition, other caffeine concentrations (4 and
8m M) were used to evoke contractures (data not shown).
Compared to the control and using 8 mM of caffeine, 1 lM
of ACPA reduced the maximum tension by 77.56 ± 6.43%
(P = 0.08), while tension-time integral was reduced by
75.46 ± 5.55% (P = 0.002, n = 5). With 4 mM caffeine,
the same concentration of ACPA reduced the maximum
tension by 80.40 ± 8.25% (P = 0.003) and tension-time
integral by 80.81 ± 10.14% (P = 0.002) compared to the
control (n = 5). Thus, these results with ACPA corroborate
that, in frog slow skeletal muscle ﬁbers, the cannabinoids
reduce tension evoked by caffeine.
Effects of Antagonist AM281 on Caffeine Contractures
in Slow Muscle Fibers
Next, we tested whether the high-afﬁnity CB1 receptor
antagonist AM281 (Howlett et al. 2002) can block the
effects of ACPA. We incubated the muscle in the recording
solution containing AM281 (1 lM) 5 min before we added
ACPA (1 lM) to the bath and kept it in the solution until
the contracture was ﬁnished. AM281 reversed the
inhibitory effect observed with ACPA alone on caffeine-
evoked tension in these slow muscle ﬁbers. As Fig. 4b
shows, maximum tension was reduced to 90.27 ± 3.07%
compared to the control and tension-time integral was not
signiﬁcantly modiﬁed (100.24 ± 10.91%, n = 5), sug-
gesting that ACPA modulates caffeine contractions by
interacting with CB1 receptors. Nevertheless, we still
observed a small decrease in the contractures, which could
have been due to a nonrelated activation of the CB1
receptors by ACPA as the reduction in tension produced by
ACPA was not fully reversed by AM281. Control experi-
ments recording caffeine contractures in the presence of
AM281 alone were also performed, and these showed no
signiﬁcant effect (data not shown). These results indicate
that ACPA reduces the caffeine-induced contracture of
slow skeletal muscle ﬁbers mainly by the activation of CB1
receptors.
Effect of PTX on Caffeine Contractures in Slow Muscle
Fibers
Cannabinoid receptors belong to the G protein-coupled
receptor family. To test whether the observed ACPA
effects are mediated through Gi/o proteins, we incubated
the cruralis muscles with PTX (2 lg/ml). Figure 4c shows
the results of the experiments under these conditions. In
slow muscle ﬁbers incubated with PTX, 1 lM of ACPA
Fig. 3 Effects of WIN 55,212-2 on caffeine contractures in slow
muscle ﬁbers. In a and b, tension decreased in the presence of WIN
55,212-2 (10 and 5 lM, respectively). Control caffeine contractures
in normal solution are also shown (upper records). This effect of WIN
55,212-2 was reversible. Different muscle bundles were used for each
experiment
Fig. 4 Effects of ACPA (1 lM) on tension evoked by caffeine in
slow skeletal muscle ﬁbers. a–c Caffeine contractures in normal
solution (upper records). a The decrease in tension with ACPA. b
Antagonist AM281 (1 lM) was coapplied with ACPA, which
reversed the inhibitory effect of ACPA. c ACPA was applied to a
bundle previously incubated with PTX
M. Huerta et al.: Effects of Cannabinoids on Skeletal Muscle 95
123had no effect on tension evoked by caffeine. The maximum
tension in the presence of ACPA, on average, was
95.69 ± 9.39%, and tension-time integral was
97.69 ± 13.37% (n = 5). These data suggest that ACPA
acts mostly through a mechanism that involves Gi/o pro-
teins. Control experiments were done in parallel, and no
signiﬁcant effect with PTX incubation was observed (data
not shown).
Effect of ACPA on Caffeine Contractures in Fast
Muscle Fibers
To investigate whether cannabinoids also can modulate
tension in fast muscle ﬁbers, we studied the effects of the
selective CB1 receptor agonist ACPA. When fast muscle
ﬁbers were incubated with ACPA (1 lM), it reduced the
maximum tension of the caffeine contracture by
56.48 ± 3.4% (P = 0.001, n = 4), and tension-time inte-
gral was reduced by 57.81 ± 2.60% (P = 0.006, n = 4) in
the second caffeine contracture (Fig. 5). This ACPA effect
was not statistically different with respect to reduction in
tension in the slow muscle ﬁbers (P[0.05). When the
CB1 antagonist receptor AM281 (1 lM) was coapplied
with ACPA, it largely reversed the effect of ACPA on
caffeine-evoked tension. Maximum tension was reduced to
87.37 ± 1.7% (P = 0.01, n = 3) and tension-time integral
to 89.77 ± 1.73% (P = 0.02, n = 3).
Furthermore, to test whether the effects of ACPA are
mediated through Gi/o proteins, we conducted experiments
preincubating the muscles with PTX. After incubating the
fast muscle ﬁbers with PTX (2 lg/ml), ACPA had no effect
on caffeine contractures (n = 3). These results are similar
to those reported above for slow ﬁbers (Fig. 4c). When we
used the cannabinoid agonist WIN 55,212-2 at a concen-
tration of 5 lM, this agonist produced a reduction in the
maximum tension of caffeine contracture to
81.16 ± 0.97% (P = 0.003, n = 4) and tension-time
integral was reduced to 72.15 ± 4.35% (P = 0.007,
n = 4), with respect to control. These results suggest that
both ACPA and WIN reduced tension in the fast muscle
ﬁbers as well.
Discussion
Frog skeletal muscle possesses two main different types of
ﬁbers: twitch or fast and slow or tonic. Fast ﬁbers give a
transient contracture in high potassium; in contrast, slow
ﬁbers generate a prolonged contracture under similar con-
ditions (Kufﬂer and Vaughan-Williams 1953; Huerta et al.
1986). This study has shown that the mRNA for the can-
nabinoid receptor CB1 is present in the frog’s fast and slow
skeletal muscle ﬁbers. Although we cannot rule out that
part of the CB1 receptor mRNA that we found was at the
level of the nerve terminal, we used thin bundles that we
carefully cleaned, removing vessels and nerves using glass
dissectors to minimize the nerve terminals as possible
sources of mRNA. The slow muscle ﬁbers that we used
were dissected from the tonic bundle of the cruralis muscle,
while the fast muscle ﬁbers were obtained from the
extensor digitorum longus digit IV. It is known that fast
muscle ﬁbers are normally mono-innervated, in contrast to
slow ﬁbers, which are multi-innervated. We found that the
mRNA expression levels for the CB1 receptor are lower in
slow skeletal muscle ﬁbers than in fast muscle ﬁbers. These
results are consistent with the evidence that only the
ortholog CB1 receptor has been reported in amphibians
(McPatland et al. 2006; Salzet et al. 2000; Wiley and
Martin 2003; Soderstrom et al. 2000; Salio et al. 2002;
Meccariello et al. 2006; Hollis et al. 2006;S a ´nchez-Pastor
et al. 2007). Recently, the presence of CB1 receptors, found
by RT-PCR, was reported in human skeletal muscle and the
murine soleus muscle (both of which contain mainly slow
muscle ﬁbers) (Krippeit-Drews and Schmidt 1992; Pagotto
et al. 2006; Cavuoto et al. 2007a). Those results are in
agreement with our ﬁndings in this work with slow muscle
ﬁbers, and we also show the presence of CB1 receptors in
fast skeletal muscle ﬁbers. CB1 receptors are mostly
localized presynaptically (Schlicker and Kathmann 2001),
but they also occur postsynaptically, e.g., in the hippo-
campus (Schweitzer 2000). Also, we recently found indi-
rect pharmacological evidence of the presence of CB1
receptors in frog fast skeletal muscle ﬁbers (Sa ´nchez-Pastor
et al. 2007).
Cannabinoid receptors are part of the endocannabinoid
system, which comprises cannabinoid receptors, along with
the endogenous cannabinoids (endocannabinoids) and the
enzymes that synthesize and degrade them. The best-
known endocannabinoid is anandamide, which is formed in
the same cell as the CB1 receptor through which it acts. It
can diffuse through the plasmalemma and can also be
released from the extracellular ﬂuid touching the presyn-
aptic terminal (Piomelli 2003; Rodriguez de Fonseca et al.
2005). Therefore, in this study we mainly used ACPA,
which is analogous to the endocannabinoid anandamide
(Hillard et al. 1999;S a ´nchez-Pastor et al. 2007).
Fig. 5 Effects of ACPA on caffeine contracture in fast muscle ﬁbers.
Experiments were done using extensor digitorum longus IV muscle.
Tension evoked by caffeine shows a great reduction in the presence of
ACPA (1 lM) compared to control tension
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well known that caffeine evokes maintained tension in fast
and slow ﬁbers, mainly by calcium release from the sar-
coplasmic reticulum (Caputo 1966; Klein et al. 1990;
Mun ˜iz et al. 1992). Moreover, in slow ﬁbers Shabala et al.
(2008) suggest that caffeine also opens the L-type Ca
2?
channels from the sarcolemma. To investigate the possible
direct effect of cannabinoids on skeletal muscle contrac-
tion, we induced caffeine contractures in the presence of
WIN 55,212-2, causing a diminution in maximum tension
and tension-time integral compared to the control. The
effect of WIN 55,212-2 was reversible and dependent on
the concentration.
To further investigate the effects of cannabinoids on
skeletal muscle contraction, we also used the synthetic
CB1-selective agonist ACPA. The results of these experi-
ments show that the cannabinoid ACPA, at 1 lM,
decreased both the maximum and the tension-time integral
of the caffeine contracture in slow and fast muscle ﬁbers.
Moreover, this effect of ACPA on fast muscle ﬁbers was
observed until the second contracture, in contrast to WIN
in slow muscle ﬁbers, which showed an effect since the
ﬁrst contracture. More studies are necessary to clarify this
mechanism. The antagonist of the CB1 receptors, AM281,
reversed this effect. In addition, both types of muscle ﬁbers
were incubated with PTX, and ACPA had no effect on the
tension evoked by caffeine. Our data suggest that ACPA
acts through a mechanism involving Gi/o proteins, and the
effect of ACPA is probably mediated by a decrease in
intracellular cAMP. With respect to ACPA, WIN and the
antagonist AM281 concentration used in this study, similar
concentrations have been used in previous studies on these
tissues (e.g., Sa ´nchez-Pastor et al. 2007). On the other
hand, in contrast with the high level of mRNA expression
that we found in the fast compared to the slow muscle
ﬁbers, the effects of cannabinoids on the induced con-
tractures in these two types of muscle ﬁbers were similar.
One reason could be that even though the mRNA expres-
sion level is higher in the fast type, the level of protein to
transcribe is lower than in the slow type (Greenbaum et al.
2003). Another explanation is the fact that the intracellular
machinery involved in the mechanisms used by cannabi-
noids to modulate tension is different in both types of
muscle ﬁbers as well as the excitation–contraction cou-
pling, which is different (Huerta et al. 1986).
With respect to differences in the magnitude of the
effects of WIN and ACPA, additional studies in the future
will elucidate these mechanisms. However, ACPA has
more selectivity for CB1 receptors and higher potency than
WIN. Another possible explanation could be the fact that
WIN and ACPA bind to a different site within the receptor.
ACPA binds at residue 192 and the WIN binding site is
possibly next to this site, in the third transmembrane
domain of CB1 (Song and Bonner 1996). Moreover, it has
been suggested that WIN binds to an uncharacterized non-
CB1 cannabinoid receptor (Breivogel et al. 2001) or va-
nilloid receptors, as has been suggested for blood vessel
smooth muscle (Dannert et al. 2007). In addition, there is
evidence of a CB1 splice variant (CB1A), which could be
the one expressed in amphibian (Rinaldi-Carmona et al.
1996; Shire et al. 1995). Thus, it would be interesting to
determine in the future the complete sequence of the can-
nabinoid receptor in this preparation to determine its nature
as it may be a CB1 splice variant.
To our knowledge, this work is the ﬁrst to show direct
evidence of the existence of CB1 receptors and the
diminishing of tension by synthetic cannabinoids on intact
frog slow and fast muscle ﬁbers. Our methodology con-
serves the entire cannabinoid signaling system of these
intact skeletal muscle ﬁbers.
Thus, the functional signiﬁcance of the cannabinoid
receptors in skeletal muscle would be the modulation of
tension. This force modulation by cannabinoids would be
done by acting on the extracellular binding site of the
membrane and/or regulating the Ca
2? release from the
sarcoplasmic reticulum (Hoock et al. 1996; Huerta et al.
1986; Krippeit-Drews and Schmidt 1992; Mun ˜iz et al.
1992; Shabala et al. 2008). However, further research is
necessary to elucidate these mechanisms.
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